Business Wire

Morgan Stanley Expands Global Inclusive Ventures Lab with Largest Single Cohort of 23 Companies

12.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Morgan Stanley (NYSE: MS) today announced the 2023 global cohort of the Inclusive Ventures Lab, with 23 companies selected across North America and Europe, the Middle East and Africa (EMEA), double the size of previous cohorts. The Lab offers a five-month in-house accelerator program for underrepresented founders of technology and technology-enabled startups in the post-seed to Series A funding round stage.

Chosen from over 7,900 applicants – more than three times last year’s pool – the selected startups represent a range of disruptive technologies in industries including healthcare, sustainable solutions, customer service, supply chain, recruiting and cybersecurity. Companies in the cohort receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners.

“We are proud to welcome the Lab’s largest cohort yet, marking our continued efforts to create a more equitable investment landscape for overlooked entrepreneurs worldwide,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group. “We are working to bridge the investment gap for underserved founders and to help correct documented market imbalances.”

The selected companies in the 2023 global cohort include the following:

  • Ad Auris empowers marketing teams, publishers and content creators to repurpose written content into high-quality audio to reach an audience of listeners (Canada)
  • Automated Architecture provides the technological infrastructure for a distributed robotic micro-factory network producing sustainable timber housing (UK)
  • Bidrento offers an all-in-one solution for tenant experience and rental property management, helping to save time and money while also reducing CO2 emissions in real estate (Estonia)
  • ByFusion provides a zero waste landfill diversion platform to transform non-recyclable plastic waste into reusable building materials (US)
  • Cult Mia is an online fashion marketplace for sustainable and ethical brands from around the world (UK)
  • DotLab develops breakthrough, actionable AI and ML technologies that lead to better health outcomes for women, starting with the diagnosis of endometriosis (US)
  • eBanqo offers businesses an omnichannel platform to drive customer engagement and support (Nigeria)
  • Encounter AI uses digital conversational ordering solutions to provide faster, friendlier and more efficient service to customers, restaurants and retailers (US)
  • FLUIX Inc. enterprise AI software saves critical infrastructure on energy costs by integrating and optimizing facility systems (US)
  • GigBridge is an online platform for construction companies to hire, onboard and pay their workforce all in one place (UK)
  • Health in Her HUE connects Black women and women of color to culturally sensitive healthcare providers, health content and community support through a digital platform (US)
  • Inicio AI delivers a virtually guided affordability assessment to help organizations save contact center costs while improving their end customer experience (UK)
  • MEDIjobs is the first virtual recruiter for the healthcare industry, filling more than 55 types of positions at a rate five times faster than a human would (US)
  • Nopalera is a collection of bath and body products powered by Mexico’s nopal cactus – an ancient symbol of Mexican culture (US)
  • OKO offers affordable and inclusive crop insurance to farmers in emerging countries using satellite weather data and mobile payment technologies (Israel)
  • Oppos provides robust cybersecurity and compliance security solutions for businesses, safeguarding data confidentiality, integrity, and availability (Canada)
  • Partsimony enables organizations to build intelligent manufacturing supply chains that are more resilient and sustainable by unifying engineering and supply chain data (US)
  • Ridelink leverages technology to enable small and medium-sized businesses to move cargo in Uganda and cross-border in six neighboring countries (Uganda)
  • serviceMob is an AI & ML-powered customer service analytics platform that helps businesses optimize operations and improve the customer experience (US)
  • Stak Mobility facilitates widespread urban electric vehicle adoption by merging space-saving vertical parking automation with fully integrated EV charging and a seamless mobile self-service experience (US)
  • Tall Poppy is a digital security company protecting employees and public facing teams from online threats (US)
  • Twipes uses bio-tech to produce flushable, biodegradable wet wipes that break down in water in three hours and biodegrade in landfills in seven days (US)
  • Unfabled is a consumer health platform that delivers personalized solutions for women by matching them with health and wellness products (UK)

“We are thrilled to bring our unique accelerator program to more entrepreneurs globally, including our first participants from Africa and the Middle East,” said Sanghamitra Karra, EMEA Head of the Inclusive Ventures Group. “It is highly rewarding to work closely with founders to take their game-changing technologies to scale and help set them up for continued success.”

“By providing these promising startups with much-needed capital, a tailored curriculum and access to investors within and beyond the Firm’s far-reaching network, we aim to ensure that more underrepresented founders can succeed,” said LaToya Wilson, Americas Head of the Inclusive Ventures Group.

Programming will run through February 2024 and culminate in a global Demo Day, when participating companies will present to potential investors, business partners and customers.

The Inclusive Ventures Lab has won multiple Gold Anthem Awards, including Most Impactful Corporate Initiative in 2022 and Corporate Social Responsibility in 2023. The program was also listed as one of Global Finance’s Best Innovation Labs of 2023.

About the Morgan Stanley Inclusive Ventures Lab

The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator program designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of underrepresented founders, which our research shows equals over four trillion dollars in unrealized returns.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations: Carrie Hall, carrie.hall@morganstanley.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye